Fabio Guolo

25PUBLICATIONS
130CO-AUTHORS
Respiratory diseasesCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Mar 07, 2026
Like a bolt from the blue: the trauma of facing acute leukemia and lymphoma diagnosis and its clinical implications.

Fabio Guolo, Paola Del Sette, Francesca Riccardi

|Feb 11, 2026
Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Salvatore Perrone, Andrea Corbingi, Calogero Vetro

|Dec 05, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Raffaele Palmieri, Fabio Guolo, Luana Fianchi

|Sep 24, 2025
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.

Fabio Guolo, Luana Fianchi, Maria Paola Martelli

|Aug 11, 2025
Real World Incidence and Etiology of Infectious Complications in Adults With Ph-Negative Acute Lymphoblastic Leukemia Treated With the Pediatric-Inspired GIMEMA LAL1913 Program. A Campus All Study.

Patrizia Zappasodi, Ludovica Calabretta, Virginia Valeria Ferretti

|Mar 06, 2025
Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.

Giovanni Marconi, Alfonso Piciocchi, Ernesta Audisio

Pageof 5

Frequent Collaborators

11 joint publications

Paola Minetto

7 joint publications

Marco Cerrano

7 joint publications

Livio Pagano

7 joint publications

Patrizia Chiusolo